BioRestorative Therapies, Inc.
BRTXAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | downgrade | Buy →Hold | Oct 6, 2026 |
| Roth MKM | maintain | Buy | Aug 14, 2024 |
| Roth MKM | maintain | Buy | Jun 12, 2024 |
| Roth MKM | maintain | Buy | Aug 14, 2023 |
| Roth Capital | maintain | Buy | Dec 7, 2022 |
| Maxim Group | maintain | Buy | Sep 28, 2022 |
| Roth Capital | maintain | Buy | Dec 1, 2021 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-1.40| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| May 13, 2026 | $-0.24 | $-6.00 | $23.2K | $312.5K |
| Mar 26, 2026 | $-7.40 | $-7.40 | $20.0K | $150.0K |
| Nov 12, 2025 | $-6.60 | $-7.20 | $11.8K | $460.0K |
| Aug 12, 2025 | $-0.30 | $-7.40 | $303.0K | $340.0K |
| May 14, 2025 | $-12.80 | $-6.40 | $25.0K | $380.0K |
| Apr 4, 2025 | $-7.50 | $-5.40 | $500.0K | $483.3K |
| Nov 12, 2024 | $-2.60 | $-8.60 | $234.0K | $475.0K |
| Aug 13, 2024 | $-10.00 | $-11.20 | $89.0K | $10.0K |
News
Biorestorative Therapies, Inc. (NASDAQ: BRTX - Get Free Report) was the target of a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 11,586 shares, a decrease of 69.2% from the August 31st total of 37,641 shares. Currently, 1.0% of the company's stock are short sold.
MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company's Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company's common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a cer…